Lv4
498 积分 2023-01-12 加入
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
2天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
2天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
4天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
9天前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
9天前
已完结
Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program
19天前
已完结
[Expert consensus on amivantamab clinical application and adverse reaction management (2025 edition)]
24天前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
1个月前
已完结
[Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)]
1个月前
已完结
Unlocking the potential of bispecific ADCs for targeted cancer therapy
1个月前
已完结
皖公网安备34019202002308
